Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotron, an Australian drug development company has reported positive results of Phase 2a trial that tested the efficacy of BIT225 in Hepatitis C virus (HCV) infected patients.
Subscribe to our email newsletter
BIT225, an orally administered, small molecule drug demonstrated good antiviral activity against HCV.
The drug specifically targets the p7 protein, a viral protein essential to virus production and replication.
During the course of the trial, patients receiving BIT225 in combination with interferon and ribavirin showed better reductions in HCV levels than patients receiving standard of care treatment alone.
BIT225 also showed good results in terms of tolerability and efficacy, the company said.